Number sleven, As much as I rag on Thero, I am still very hopeful that
he will deliver a BO for AMRN. One reason I post what I post is the hope
that if others feel the same way they too will express their views to
IR or the AMRN BOD. One has to believe that if we as small investors are
angry, imagine how the institutional investors must feel?
I hope the pressure exerted on JT and the BOD will be enough for them
to get the message and begin to act on it. Perhaps discussions with BP
are under way so they can at a minimum get Europe off to a good start.
The hiring of 800 sales reps was folly. (I had hoped JT was expanding
the sales force at the time as a way to get BP to pay up...well, if that
were the case it certainly did not work out very well.
My view is Europe alone is worth more than $20 in a BO. Only with a BP
BO will Vascepa sales be optimized throughout the world. If (someday)
the FDA comes to rescue Vascepa it will most likely be with BP ownership.
Imagine what Dr. Gottlieb would be saying about Vascepa if PFE had
acquired AMRN long ago. As far as I am concerned, JT should either
be actively engaged in the sale of the company or he should resign.
(If not actually removed by the BOD...they know how he is doing...not us.)
Market Data 
Markets 
AI
